VKTX 42.25 (+1.83%)
US92686J1060BiotechnologyBiotechnology

Viking Therapeutics (VKTX) Financial Metrics

This table shows a selected set of financial data points of Viking Therapeutics (VKTX). You can choose which elements to display by selecting the desired chart and column.

MarketCap

Total Revenue

Free CashFlow

Year EPS Dividend Yield PE Ratio MarketCap Return On Assets Total Revenue Free CashFlow EBITDA Net Income Cash
2023 -0.91 0 -20.44 1.76B -0.32 0 -73.38M -100.54M -85.9M 55.52M
2022 -0.9 0 -10.49 722.24M -0.36 0 -48.4M -70.02M -68.87M 36.63M
2021 -0.71 0 -6.46 355.11M -0.24 10.7K -47.59M -55.39M -54.99M 26.37M
2020 -0.54 0 -10.35 408.72M -0.15 10.73K -21.78M -42.43M -39.5M 29.12M
2019 -0.36 0 -22.39 577.11M -0.09 0 -24.75M -25.52M -25.78M 8.38M
2018 -0.38 0 -19.96 440.49M -0.14 0 -18.76M -21.66M -22.06M 24.78M
2017 -0.79 0 -5.13 105.47M -1.12 0 -14.76M -19.3M -20.58M 8.99M
2016 -0.91 0 -1.31 19.37M -0.98 0 -11.07M -12.92M -14.73M 3.08M
2015 -3.68 0 -0.93 21.67M -2.53 0 -8.73M -22.42M -23.4M 768.55K
2014 -5.08 0 0 0 -13.58 0 -1.59M -21.26M -21.88M 755.86K
2013 -0.03 0 0 0 -1.62 0 -78.24K -121.7K -146.25K 179.62K
2012 0 0 0 0 0 0 0 0 0 0

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.